News
Therapeutic Solutions International Announces Clinical Trial Assessing “Kaihani Score” Proprietary Biomarker Based Assay for Quantifying Gambling Addiction

OCEANSIDE, Calif., Dec. 2, 2020 /PRNewswire/ — Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today opening of a clinical trial assessing ability of its proprietary “Kaihani Score” for quantifying severity of gambling addiction utilizing immunology-based protein biomarkers.
The study, which is listed on the National Institutes of Health (NIH) clinicaltrials.gov website1 will assess correlation between immune associated proteins which the Company previously found associated with addictive behaviors, and validated psychological means of quantifying gambling addiction.
“Online gambling represents an over 50-billion-dollar annual global market2, with a significant proportion of participants possessing addictive-like behavior. We sought to expand our work in the area of biological quantification of pathological behaviors to the significant problem of gambling addiction, which in comparison to other addictions, is highly understudied” said Famela Ramos, Vice President of Business Development for the Company.
“Having seen close friends of mine undergo severe consequences as a result of their gambling addictions, I am honored that my colleagues at Therapeutic Solutions proposed we name our bio-assay for this pathology based on my surname” said Wais Kaihani, co-inventor of the Kaihani Score and consultant to the Company. “The correlations between various proteins associated with addictive behavior and cancer progression are astonishing. I am thankful for the leadership of our Company for supporting this investigation into what initially was a “gut feeling”.
“We at Therapeutic Solutions International are pinpoint focused on developing, rapidly assessing, and commercializing game-changing technologies. We are thankful for the support our clinical trials have been receiving and are excited to launch our 3rd trial listed on the federal database” said Timothy Dixon, co-inventor and President and CEO of the Company. “By scientifically establishing the connection between abhorrent immunity, and behavioral abnormalities such as gambling, we hope to initiate a new wave of scientific research focused on leveraging the brain-immune interaction.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ and Campbell Neurosciences at https://www.campbellneurosciences.com
1 https://www.clinicaltrials.gov/ct2/show/NCT04648007
2 https://www.grandviewresearch.com/industry-analysis/online-gambling-market
SOURCE Therapeutic Solutions International
News
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against SolarWinds Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Jan. 20, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against SolarWinds Corporation (“SolarWinds” or “the Company”) (NYSE: SWI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 24, 2020 and December 15, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 5, 2021.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. SolarWinds' Orion monitoring product suffered from a vulnerability since the middle of 2020 that allowed hackers to force access to servers running the compromised software. The Company's update server was not adequately secured, for example, its password was “solarwinds123.” The Company's customers, including Microsoft, the Federal government, and others were left vulnerable to hackers. This vulnerability and subsequent hacks of these organizations led to severe reputational harm for the Company. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about SolarWinds, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View original content to download multimedia:http://www.prnewswire.com/news-releases/investor-action-alert-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-solarwinds-corporation-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301211794.html
SOURCE The Schall Law Firm
News
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Triterras, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Jan. 20, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Triterras, Inc. (“Triterras” or “the Company”) (NASDAQ: TRIT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between August 20, 2020 and December 16, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before February 19, 2021.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Triterras misled investors about the extent to which its revenue growth relied on Rhodium referring users to the Company's Kratos platform. Rhodium suffered from severe financial problems, which in turn jeopardized the growth of Triterras' Kratos platform. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Triterras, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View original content to download multimedia:http://www.prnewswire.com/news-releases/investor-action-alert-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-triterras-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301211788.html
SOURCE The Schall Law Firm
News
UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Covia Holdings Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Jan. 20, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Covia Holdings Corporation (“Covia” or “the Company”) (OTC: CVIAQ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between March 15, 2016 and June 29, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before February 8, 2021.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Covia touted its “value-added” proprietary proppants that failed to be any more effective than ordinary sand. The Company's revenues were dependent on its proprietary proppant, which it misrepresented to the market. When Company insiders raised issues with the proppants, it did not take action to rectify the situation. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Covia, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View original content to download multimedia:http://www.prnewswire.com/news-releases/upcoming-deadline-reminder-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-covia-holdings-corporation-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301211783.html
SOURCE The Schall Law Firm